Status:

COMPLETED

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Brain and Central Nervous System Tumors

Lymphoma

Eligibility:

All Genders

Phase:

NA

Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab...

Detailed Description

OBJECTIVES: Primary * Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy co...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed untreated primary CNS lymphoma (PCNSL) confirmed by 1 of the following methods:
  • Brain biopsy or resection
  • Patients diagnosed with T-cell PCNSL allowed but will not receive rituximab on study
  • Cerebrospinal fluid (CSF) cytology
  • Positive CSF cytology with or without measurable intracranial disease
  • Vitreal biopsy
  • Histologic confirmation of vitreal lymphoma with measurable intracranial tumor
  • No evidence of systemic non-Hodgkin's lymphoma
  • CT scan of chest, abdomen, and pelvis or bone marrow biopsy negative for extracerebral source of lymphoma
  • No evidence of pleural effusions or ascites
  • MRI of brain and spine (plus gadolinium) must have measurable contrast enhancing disease unless CSF cytology is positive
  • PATIENT CHARACTERISTICS:
  • Karnofsky performance score 50-100%
  • HIV negative
  • Creatinine clearance ≥ 50 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • PRIOR CONCURRENT THERAPY:
  • No concurrent salicylates, nonsteroidal anti-inflammatory drugs, sulfonamides, or penicillins within the past week

Exclusion

    Key Trial Info

    Start Date :

    September 1 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 1 2012

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT00416819

    Start Date

    September 1 2003

    End Date

    February 1 2012

    Last Update

    August 20 2015

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.